AVITA Medical (RCEL) EBIAT (2018 - 2025)
AVITA Medical (RCEL) has disclosed EBIAT for 7 consecutive years, with -$11.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT changed 0.28% year-over-year to -$11.6 million, compared with a TTM value of -$48.6 million through Dec 2025, up 21.44%, and an annual FY2025 reading of -$48.6 million, up 21.44% over the prior year.
- EBIAT was -$11.6 million for Q4 2025 at AVITA Medical, up from -$13.2 million in the prior quarter.
- Across five years, EBIAT topped out at $29.2 million in Q4 2022 and bottomed at -$18.7 million in Q1 2024.
- Average EBIAT over 4 years is -$8.6 million, with a median of -$10.2 million recorded in 2023.
- The sharpest move saw EBIAT plummeted 124.17% in 2023, then soared 35.56% in 2025.
- Year by year, EBIAT stood at $29.2 million in 2022, then tumbled by 124.17% to -$7.1 million in 2023, then crashed by 64.03% to -$11.6 million in 2024, then decreased by 0.28% to -$11.6 million in 2025.
- Business Quant data shows EBIAT for RCEL at -$11.6 million in Q4 2025, -$13.2 million in Q3 2025, and -$9.9 million in Q2 2025.